Menu
Canopy
loram ipsum
Building the first antigen specific curative therapies for
autoimmune diseases
Problem statement
Antibodies, the mainstay of immunity, sometimes turn against us, attacking our body’s own constituents and causing a chronic, sometimes life-threatening disease. We call it Autoimmunity.
Despite the fact that autoreactive antibodies are a rare minority of the patient’s antibody repertoire, the standard of care for many decades is general, nonspecific immunosuppression.
High-dose steroids, anti- B-cell agents, IVIg, plasmapheresis, Complement, and FcRN inhibitors are all being utilized to suppress the patient’s immune system while trying to balance between symptoms and side effects.
This approach suffers from major setbacks including limited efficacy
(20-70% remains symptomatic), a myriad of side effects (e.g. invasive infections, cancer), and the fact it does not provide the hope for a cure.
First principles solution – Reverse Immunization™
A new class of biologics that will allow the elimination
of antigen-specific immunity in a highly selective, nonimmunosuppressive, and irreversible manner
Our Reverse Immunization™ platform, combining rational design with powerful computational tools is a pipeline of biologics that eliminate autoreactive immune cells in a highly selective and irreversible manner using a unique targeting approach that keeps
the remaining immune system intact and the patient immune-competent.
Canopy’s unique approach captures the promise of long-term remission and cure, by targeting the disease’s root cause rather than utilizing various forms of wide and non-specific immune-suppression.
כתוב את הכותרת כאן
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Market and Strategy
Canopy’s platform is targeting a massive market opportunity with a lead product (Myasthenia Gravis) targeting a ~$2B market (10% CAGR).
Our immediate platform assets are targeting an additional ~$7B
opportunity, including Membranous Nephropathy, Pemphigus Vulgaris, MuSK MG, ITP, and more.
We focus on high unmet clinical needs with compelling health economics.
Most of our pipeline assets are targeting orphan diseases, providing a favorable regulatory path, extended exclusivity, and tax
benefits.
Our strategy includes an independent development of our lead product, combined with partnering around our pipeline indications.
Financing and alliances
Canopy started to operate in Q1-2020, with a seed investment led by TLV Partners, and a SAFE in Q4-20 from a group of high net worth, biotech savvy, angel investors.
The company currently has a runway of over 18 months.
We are currently exploring both a few financial investment options and a few potential partnerships with large biopharma companies around one or more of our pipeline products.
